Scientists from ENDECE Neural announced today that new pre-clinical evidence that the company’s lead compound, NDC-1308, induces remyelination in experimental models of MS will be presented at the 45th annual meeting of the American Society for Neurochemistry (ASN) in Long Beach, Calif.
Help employers find you! Check out all the jobs and post your resume.
